| Market Cap | 185.24M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -51.32M | Forward P/E | -1.13 | EPS next Y | - | 50D Avg Chg | -21.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -84.00% |
| Recommedations | 3.00 | Quick Ratio | 0.04 | Shares Outstanding | 1.22B | 52W Low Chg | 35.00% |
| Insider Own | 0.61% | ROA | -100.64% | Shares Float | 1.20B | Beta | 0.12 |
| Inst Own | 0.02% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.20 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,339,420 | Target Price | - |
| Oper. Margin | - | Earnings Date | Oct 21 | Volume | 4,875,334 | Change | -3.38% |
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.